Brought to you by 
Regeneron takes back rights to two ophthalmic antibody programs under partnership with Sanofi
02 Jul 2013
Executive Summary
Therapeutic antibody developer Regeneron Pharmaceuticals Inc. is reaping the benefits of a continuing relationship with Sanofi, by licensing back rights to two antibody programs it discovered, but partnered with the Big Pharma in a 2007 deal.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Regeneron takes back rights to two ophthalmic antibody programs under partnership with Sanofi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice